KCTD1 mutants in scalp‑ear‑nipple syndrome and AP‑2α P59A in Char syndrome reciprocally abrogate their interactions, but can regulate Wnt/β‑catenin signaling

Hu,Lingyu; Chen,Li; Yang,Liu; Ye,Zi; Huang,Wenhuan; Li,Xinxin; Liu,Qing; Qiu,Junlu; Ding,Xiaofeng

doi:10.3892/mmr.2020.11457

KCTD1 mutants in scalp‑ear‑nipple syndrome and AP‑2α P59A in Char syndrome reciprocally abrogate their interactions, but can regulate Wnt/β‑catenin signaling

Authors:
- Lingyu Hu
- Li Chen
- Liu Yang
- Zi Ye
- Wenhuan Huang
- Xinxin Li
- Qing Liu
- Junlu Qiu
- Xiaofeng Ding
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Third Xiangya Hospital of The Central South University, Changsha, Hunan 410013, P.R. China, Key Laboratory of Protein Chemistry and Development Biology of State Education Ministry of China, College of Life Science, Hunan Normal University, Changsha, Hunan 410081, P.R. China, Yali High School of Changsha, Changsha, Hunan 410007, P.R. China
Published online on: August 24, 2020 https://doi.org/10.3892/mmr.2020.11457
Pages: 3895-3903
Copyright: © Hu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Potassium‑channel tetramerization-domain-containing 1 (KCTD1) mutations are reported to result in scalp‑ear‑nipple syndrome. These mutations occur in the conserved broad‑complex, tramtrack and bric a brac domain, which is associated with inhibited transcriptional activity. However, the mechanisms of KCTD1 mutants have not previously been elucidated; thus, the present study aimed to investigate whether KCTD1 mutants affect their interaction with transcription factor AP‑2α and their regulation of the Wnt pathway. Results from the present study demonstrated that none of the ten KCTD1 mutants had an inhibitory effect on the transcriptional activity of AP‑2α. Co‑immunoprecipitation assays demonstrated that certain mutants exhibited changeable localization compared with the nuclear localization of wild‑type KCTD1, but no KCTD1 mutant interacted with AP‑2α. Almost all KCTD1 mutants, except KCTD1 A30E and H33Q, exhibited differential inhibitory effects on regulating TOPFLASH luciferase reporter activity. In addition, the interaction region of KCTD1 to the PY motif (amino acids 59‑62) in AP‑2α was identified. KCTD1 exhibited no suppressive effects on the transcriptional activity of the AP‑2α P59A mutant, resulting in Char syndrome, a genetic disorder characterized by a distinctive facial appearance, heart defect and hand abnormalities, by altered protein cellular localization that abolished protein interactions. However, the P59A, P60A, P61R and 4A AP‑2α mutants inhibited TOPFLASH reporter activity. Moreover, AP‑2α and KCTD1 inhibited β‑catenin expression levels and SW480 cell viability. The present study thus identified a putative mechanism of disease‑related KCTD1 mutants and AP‑2α mutants by disrupting their interaction with the wildtype proteins AP‑2α and KCTD1 and influencing the regulation of the Wnt/β‑catenin pathway.

View Figures

View References

1	Finlay AY and Marks R: An hereditary syndrome of lumpy scalp, odd ears and rudimentary nipples. Br J Dermatol. 99:423–430. 1978. View Article : Google Scholar : PubMed/NCBI
2	van Steensel MA, Celli J, van Bokhoven JH and Brunner HG: Probing the gene expression database for candidate genes. Eur J Hum Genet. 7:910–919. 1999. View Article : Google Scholar : PubMed/NCBI
3	Marneros AG, Beck AE, Turner EH, McMillin MJ, Edwards MJ, Field M, de Macena Sobreira NL, Perez ABA, Fortes JAR, Lampe AK, et al: Mutations in KCTD1 cause scalp-ear-nipple syndrome. Am J Hum Genet. 92:621–626. 2013. View Article : Google Scholar : PubMed/NCBI
4	Zhang J, Hagopian-Donaldson S, Serbedzija G, Elsemore J, Plehn-Dujowich D, McMahon AP, Flavell RA and Williams T: Neural tube, skeletal and body wall defects in mice lacking transcription factor AP-2. Nature. 381:238–241. 1996. View Article : Google Scholar : PubMed/NCBI
5	Ahituv N, Erven A, Fuchs H, Guy K, Ashery-Padan R, Williams T, de Angelis MH, Avraham KB and Steel KP: An ENU-induced mutation in AP-2alpha leads to middle ear and ocular defects in doarad mice. Mamm Genome. 15:424–432. 2004. View Article : Google Scholar : PubMed/NCBI
6	Sletten LJ and Pierpont ME: Familial occurrence of patent ductus arteriosus. Am J Med Genet. 57:27–30. 1995. View Article : Google Scholar : PubMed/NCBI
7	Zhao F, Weismann CG, Satoda M, Pierpont ME, Sweeney E, Thompson EM and Gelb BD: Novel TFAP2B mutations that cause char syndrome provide a genotype-phenotype correlation. Am J Hum Genet. 69:695–703. 2001. View Article : Google Scholar : PubMed/NCBI
8	Li H, Sheridan R and Williams T: Analysis of TFAP2A mutations in branchio-oculo-facial syndrome indicates functional complexity within the AP-2α DNA-binding domain. Hum Mol Genet. 22:3195–3206. 2013. View Article : Google Scholar : PubMed/NCBI
9	Milunsky JM, Maher TA, Zhao G, Roberts AE, Stalker HJ, Zori RT, Burch MN, Clemens M, Mulliken JB, Smith R and Lin AE: TFAP2A mutations result in branchio-oculo-facial syndrome. Am J Hum Genet. 82:1171–1177. 2008. View Article : Google Scholar : PubMed/NCBI
10	Milunsky JM, Maher TM, Zhao G, Wang Z, Mulliken JB, Chitayat D, Clemens M, Stalker HJ, Bauer M, Burch M, et al: Genotype-phenotype analysis of the branchio-oculo-facial syndrome. Am J Med Genet A 155A. 22–32. 2011. View Article : Google Scholar
11	Dumitrescu AV, Milunsky JM, Longmuir SQ and Drack AV: A family with branchio-oculo-facial syndrome with primarily ocular involvement associated with mutation of the TFAP2A gene. Ophthalmic Genet. 33:100–106. 2012. View Article : Google Scholar : PubMed/NCBI
12	Thomeer HG, Crins TT, Kamsteeg EJ, Buijsman W, Cruysberg JR, Knoers NV and Cremers CWRJ: Clinical presentation and the presence of hearing impairment in branchio-oculo-facial syndrome: A new mutation in the TFAP2A gene. Ann Otol Rhinol Laryngol. 119:806–814. 2010. View Article : Google Scholar : PubMed/NCBI
13	Ding X, Luo C, Zhou J, Zhong Y, Hu X, Zhou F, Ren K, Gan L, He A, Zhu J, et al: The interaction of KCTD1 with transcription factor AP-2alpha inhibits its transactivation. J Cell Biochem. 106:285–295. 2009. View Article : Google Scholar : PubMed/NCBI
14	Zarelli VE and Dawid IB: Inhibition of neural crest formation by Kctd15 involves regulation of transcription factor AP-2. Proc Natl Acad Sci USA. 110:2870–2875. 2013. View Article : Google Scholar : PubMed/NCBI
15	Heffer A, Marquart GD, Aquilina-Beck A, Saleem N, Burgess HA and Dawid IB: Generation and characterization of Kctd15 mutations in zebrafish. PLoS One. 12:e01891622017. View Article : Google Scholar : PubMed/NCBI
16	Dutta S and Dawid IB: Kctd15 inhibits neural crest formation by attenuating Wnt/beta-catenin signaling output. Development. 137:3013–3018. 2010. View Article : Google Scholar : PubMed/NCBI
17	Li Q and Dashwood RH: Activator protein 2alpha associates with adenomatous polyposis coli/beta-catenin and inhibits beta-catenin/T-cell factor transcriptional activity in colorectal cancer cells. J Biol Chem. 279:45669–45675. 2004. View Article : Google Scholar : PubMed/NCBI
18	Li X, Chen C, Wang F, Huang W, Liang Z, Xiao Y, Wei K, Wan Z, Hu X, Xiang S, et al: KCTD1 suppresses canonical Wnt signaling pathway by enhancing β-catenin degradation. PLoS One. 9:e943432014. View Article : Google Scholar : PubMed/NCBI
19	Ding X, Fan C, Zhou J, Zhong Y, Liu R, Ren K, Hu X, Luo C, Xiao S, Wang Y, et al: GAS41 interacts with transcription factor AP-2beta and stimulates AP-2beta-mediated transactivation. Nucleic Acids Res. 34:2570–2578. 2006. View Article : Google Scholar : PubMed/NCBI
20	Ding X, Yang Z, Zhou F, Wang F, Li X, Chen C, Li X, Hu X, Xiang S and Zhang J: Transcription factor AP-2α regulates acute myeloid leukemia cell proliferation by influencing hoxa gene expression. Int J Biochem Cell Biol. 45:1647–1656. 2013. View Article : Google Scholar : PubMed/NCBI
21	Ding XF, Luo C, Ren KQ and Zhang J, Zhou JL, Hu X, Liu RS, Wang Y, Gao X and Zhang J: Characterization and expression of a human KCTD1 gene containing the BTB domain, which mediates transcriptional repression and homomeric interactions. DNA Cell Biol. 27:257–265. 2008. View Article : Google Scholar : PubMed/NCBI
22	Clevers H: Wnt/beta-catenin signaling in development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
23	Baron R and Kneissel M: WNT signaling in bone homeostasis and disease: From human mutations to treatments. Nat Med. 19:179–192. 2013. View Article : Google Scholar : PubMed/NCBI
24	Gay A and Towler DA: Wnt signaling in cardiovascular disease: Opportunities and challenges. Curr Opin Lipidol. 28:387–396. 2017. View Article : Google Scholar : PubMed/NCBI
25	Ng L, Kaur P, Bunnag N, Suresh J, Sung ICH, Tan QH, Gruber J and Tolwinski NS: WNT signaling in disease. Cells. 8:8262019. View Article : Google Scholar
26	Li X, Peng H, Schultz DC, Lopez-Guisa JM, Rauscher FJ III and Marmorstein R: Structure-function studies of the BTB/POZ transcriptional repression domain from the promyelocytic leukemia zinc finger oncoprotein. Cancer Res. 59:5275–5282. 1999.PubMed/NCBI
27	Fedele M, Benvenuto G, Pero R, Majello B, Battista S, Lembo F, Vollono E, Day PM, Santoro M, Lania L, et al: A novel member of the BTB/POZ family, PATZ, associates with the RNF4 RING finger protein and acts as a transcriptional repressor. J Biol Chem. 275:7894–7901. 2000. View Article : Google Scholar : PubMed/NCBI
28	Hoatlin ME, Zhi Y, Ball H, Silvey K, Melnick A, Stone S, Arai S, Hawe N, Owen G, Zelent A and Licht JD: A novel BTB/POZ transcriptional repressor protein interacts with the fanconi anemia group C protein and PLZF. Blood. 94:3737–3747. 1999. View Article : Google Scholar : PubMed/NCBI
29	Kelly KF and Daniel JM: POZ for effect--POZ-ZF transcription factors in cancer and development. Trends Cell Biol. 16:578–587. 2006. View Article : Google Scholar : PubMed/NCBI
30	Kojima S, Hatano M, Okada S, Fukuda T, Toyama Y, Yuasa S, Ito H and Tokuhisa T: Testicular germ cell apoptosis in Bcl6-deficient mice. Development. 128:57–65. 2001.PubMed/NCBI
31	Shaffer AL, Yu X, He Y, Boldrick J, Chan EP and Staudt LM: BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity. 13:199–212. 2000. View Article : Google Scholar : PubMed/NCBI
32	Barna M, Hawe N, Niswander L and Pandolfi PP: Plzf regulates limb and axial skeletal patterning. Nat Genet. 25:166–172. 2000. View Article : Google Scholar : PubMed/NCBI
33	Costoya JA, Hobbs RM, Barna M, Cattoretti G, Manova K, Sukhwani M, Orwig KE, Wolgemuth DJ and Pandolfi PP: Essential role of Plzf in maintenance of spermatogonial stem cells. Nat Genet. 36:653–659. 2004. View Article : Google Scholar : PubMed/NCBI
34	Huang C, Hatzi K and Melnick A: Lineage-specific functions of Bcl-6 in immunity and inflammation are mediated by distinct biochemical mechanisms. Nat Immunol. 14:380–388. 2013. View Article : Google Scholar : PubMed/NCBI
35	Ahmad KF, Engel CK and Prive GG: Crystal structure of the BTB domain from PLZF. Proc Natl Acad Sci USA. 95:12123–12128. 1998. View Article : Google Scholar : PubMed/NCBI
36	Carey RM, Balcz BA, Lopez-Coviella I and Slack BE: Inhibition of dynamin-dependent endocytosis increases shedding of the amyloid precursor protein ectodomain and reduces generation of amyloid beta protein. BMC Cell Biol. 6:302005. View Article : Google Scholar : PubMed/NCBI
37	Char F: Peculiar facies with short philtrum, duck-bill lips, ptosis and low-set ears-a new syndrome? Birth Defects Orig Artic Ser. 14:303–305. 1978.PubMed/NCBI
38	Marston DJ, Roh M, Mikels AJ, Nusse R and Goldstein B: Wnt signaling during caenorhabditis elegans embryonic development. Methods Mol Biol. 469:103–111. 2008. View Article : Google Scholar : PubMed/NCBI
39	Munoz-Descalzo S, Hadjantonakis AK and Arias AM: Wnt/ß-catenin signalling and the dynamics of fate decisions in early mouse embryos and embryonic stem (ES) cells. Semin Cell Dev Biol. 47-48:101–109. 2015. View Article : Google Scholar : PubMed/NCBI
40	Wang B, Tian T, Kalland KH, Ke X and Qu Y: Targeting Wnt/β-catenin signaling for cancer immunotherapy. Trends Pharmacol Sci. 39:648–658. 2018. View Article : Google Scholar : PubMed/NCBI
41	Wang W, Smits R, Hao H and He C: Wnt/β-catenin signaling in liver cancers. Cancers (Basel). 11:9262019. View Article : Google Scholar
42	Jung YS and Park JI: Wnt signaling in cancer: Therapeutic targeting of Wnt signaling beyond β-catenin and the destruction complex. Exp Mol Med. 52:183–191. 2020. View Article : Google Scholar : PubMed/NCBI
43	Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A, Koyama K, Utsunomiya J, Baba S and Hedge P: Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science. 253:665–669. 1991. View Article : Google Scholar : PubMed/NCBI
44	Nakamura Y, Nishisho I, Kinzler KW, Vogelstein B, Miyoshi Y, Miki Y, Ando H, Horii A and Nagase H: Mutations of the adenomatous polyposis coli gene in familial polyposis coli patients and sporadic colorectal tumors. Princess Takamatsu Symp. 22:285–292. 1991.PubMed/NCBI
45	Suraweera N, Robinson J, Volikos E, Guenther T, Talbot I, Tomlinson I and Silver A: Mutations within Wnt pathway genes in sporadic colorectal cancers and cell lines. Int J Cancer. 119:1837–1842. 2006. View Article : Google Scholar : PubMed/NCBI
46	Colnot S: Focusing on beta-catenin activating mutations to refine liver tumor profiling. Hepatology. 64:1850–1852. 2016. View Article : Google Scholar : PubMed/NCBI
47	Fujikura K, Akita M, Ajiki T, Fukumoto T, Itoh T and Zen Y: Recurrent mutations in APC and CTNNB1 and activated Wnt/β-catenin signaling in intraductal papillary neoplasms of the bile duct: A whole exome sequencing study. Am J Surg Pathol. 42:1674–1685. 2018. View Article : Google Scholar : PubMed/NCBI